Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus
A study combining in silico modeling with in vitro and in vivo experiments found that human β-defensin DEFB103 both enhances and attenuates chemokine and cytokine responses to a pro-inflammatory bacterial stimulus, with the direction depending on the peptide's concentration, the timing of exposure relative to the antigen, and the specific cell or animal system tested, with the authors emphasizing that the underlying signaling mechanism driving this bidirectional switch still needs to be defined.
Dr. Monica Raina
Periodontist
Table of contents
Share
Background & context
Human β-defensin DEFB103 (hBD-3) is a small antimicrobial peptide found throughout the oronasal cavity — in nasal mucus, saliva, and gingival crevicular fluid — where it plays an established role in innate host defense. Beyond direct antimicrobial activity, DEFB103 is increasingly implicated in shaping the inflammatory response itself, with relevance to mucosal infections, head and neck squamous cell carcinoma (where it is overexpressed and may function as a macrophage chemoattractant), autoimmune and auto-inflammatory disease, and severe trauma.
Yet the literature on DEFB103’s effect on chemokine and cytokine production is contradictory: some studies show it amplifies pro-inflammatory responses, others show it suppresses them. This dichotomy — DEFB103 acting as both stimulant and attenuator — has persisted across multiple research groups without a clear explanation of what determines which direction the effect runs.
How the question evolved
Early work on defensin-modulated inflammation asked a binary question: does DEFB103 enhance or suppress a given cytokine response? Different labs, using different conditions, kept getting different answers to that same yes/or-no question.
A more systematic approach reveals that the directionality of DEFB103’s effect is governed by at least three interacting variables, identified using a combined in silico/in vitro/in vivo strategy:
Concentration dependence | Temporal sequencing | Biological system |
|---|---|---|
Low DEFB103 concentrations (0.2–2.0 µM) tended to attenuate HagB-induced responses, while very high concentrations (20 µM, or 10,000:1 molar excess in the simulation model) instead enhanced the same responses | Mixing DEFB103 with the antigen before exposure (co-treatment) generally attenuated responses, while giving DEFB103 one hour before or after antigen exposure (pre-/post-treatment) generally enhanced them | The bidirectional (both-enhance-and-attenuate) pattern was fully expressed only in human myeloid dendritic cells; murine JAWSII dendritic cells showed only attenuation, and intact mice showed predominantly only enhancement |
This shift reframes DEFB103’s “contradictory” literature not as a methodological problem to be resolved by picking the “correct” result, but as a genuinely context-dependent biological switch, in which concentration, timing, and the cell/organism system jointly determine the outcome for any given chemokine or cytokine.
Why this matters at different levels
For interpreting prior conflicting literature: Studies reporting that defensins are purely pro-inflammatory or purely anti-inflammatory were likely each capturing one slice of a multivariable response surface, rather than describing two incompatible biological realities.
For modeling complex cellular responses: An in silico simulation of dendritic cell signaling — built from roughly 2,560 biological species and over 9,300 modeled interactions — correctly predicted both the attenuating effect of moderate DEFB103 over-expression and the paradoxical enhancing effect of very high over-expression, before either was confirmed experimentally, demonstrating that network-level modeling can anticipate counterintuitive dose-dependent reversals.
For translating findings across species and systems: The same stimulus (HagB) and the same modulator (DEFB103) produced systematically different directional effects in human dendritic cells, mouse dendritic cell lines, and live mice — a caution against assuming that an in vitro human cell finding will generalize cleanly to animal models or vice versa.
The open challenge
Why concentration and timing flip the direction of the response is not yet mechanistically resolved. Plausible contributors include DEFB103 binding directly to the antigen and altering its ability to engage Toll-like receptors, DEFB103 and antigen synergistically activating overlapping pathways when delivered separately, and DEFB103’s capacity to rapidly enter cells and act intracellularly — but distinguishing between these possibilities will require dissecting the specific signaling intermediates and transcription factors involved.
Going forward
Future work needs to move from characterizing the conditions under which DEFB103 flips between enhancing and attenuating inflammation toward identifying the specific pathway intermediates responsible for that switch. Clarifying this mechanism matters beyond basic biology: it bears directly on understanding mucosal tissue homeostasis under normal antigenic load, and on diseases — such as oral squamous cell carcinoma — where DEFB103 overexpression coincides with intense, possibly self-reinforcing inflammation.
